Top 20 of Cardiovascular Diseases

Article title # Publications/# Citations

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

2003: National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee; GLBakris; HRBlack; AVChobanian; WCCushman; LAGreen; JLIzzo; ... DWJones; BJMaterson; SOparil; EJRoccella; JTWright;

1798

K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.

2002: National Kidney Foundation;

1241

Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

2003: Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee; GLBakris; HRBlack; AVChobanian; WCCushman; LAGreen; JLIzzo; ... DWJones; BJMaterson; SOparil; EJRoccella; JTWright;

1231

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization.

2004: GMChertow; DFan; ASGo; CYHsu; CEMcCulloch;

868

Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond.

2008: RBD'Agostino; MJPencina; RSVasan;

763

Effects of intensive glucose lowering in type 2 diabetes.

2008: Action to Control Cardiovascular Risk in Diabetes Study Group; JTBigger; JBBuse; RPByington; WCCushman; WTFriedewald; SGenuth; HCGerstein; ... DCGoff; RHGrimm; FIsmail-Beigi; MEMiller; JLProbstfield; DGSimons-Morton;

755

Prevalence of chronic kidney disease in the United States.

2007: JCoresh; PEggers; JWKusek; ASLevey; JManzi; ESelvin; LAStevens; FVan Lente;

703

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity.

2009: American Heart Association; Hational Heart, Lung, and Blood Institute; International Association for the Study of Obesity; International Atherosclerosis Society; International Diabetes Federation Task Force on Epidemiology and Prevention; World Heart Federation; KGAlberti; JICleeman; ... KADonato; RHEckel; JCFruchart; SMGrundy; WPJames; CMLoria; SCSmith; PZZimmet;

665

Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

2002: Prospective Studies Collaboration; RClarke; RCollins; SLewington; RPeto; NQizilbash;

663

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.

2008: ADVANCE Collaborative group; LBillot; SBompoint; JChalmers; MCooper; BEde Galan; PGlasziou; DGrobbee; ... PHamet; SHarrap; SHeller; RJoshi; LLiu; SMacMahon; GMancia; MMarre; CEMogensen; BNeal; CPan; APatel; NPoulter; ARodgers; FTravert; BWilliams; MWoodward;

617

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association.

2003: American Heart Association; Centers for Disease Control and Prevention; RWAlexander; JLAnderson; ROCannon; MCriqui; YYFadl; SPFortmann; ... YHong; GAMensah; GLMyers; TAPearson; NRifai; SCSmith; KTaubert; RPTracy; FVinicor;

613

Free radicals and antioxidants in normal physiological functions and human disease.

2006: MTCronin; DLeibfritz; MMazur; JMoncoľ; JTelser; MValko;

608

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1994:

593

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

2008: JUPITER Study Group; EDanielson; FAFonseca; JGenest; RJGlynn; AMGotto; JJKastelein; WKoenig; ... PLibby; AJLorenzatti; JGMacFadyen; BGNordestgaard; PMRidker; JShepherd; JTWillerson;

569

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

2000: JBosch; GDagenais; RDavies; JPogue; PSleight; SYusuf;

563

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.

2005: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group; JYBacklund; PACleary; SMGenuth; JMLachin; DMNathan; TJOrchard; PRaskin; BZinman;

543

Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.

2007: SENissen; KWolski;

528

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

2000: JEBuring; CHHennekens; PMRidker; NRifai;

526

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

2004: American College of Cardiology Foundation; American Heart Association; National Heart, Lung, and Blood Institute; HBBrewer; LTClark; JICleeman; SMGrundy; DBHunninghake; ... CNMerz; RCPasternak; SCSmith; NJStone;

516

The metabolic syndrome--a new worldwide definition.

2005 Sep 24-30: IDF Epidemiology Task Force Consensus Group; KGAlberti; JShaw; PZimmet;

510